Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 23Gemcitabine 9Nivolumab 7Carboplatin 7Trastuzumab 6Early Intervention, Educational 6avelumab 5atezolizumab 5Docetaxel 5Cisplatin 5cemiplimab 4Standard of Care 4Psychiatric Rehabilitation 4Paclitaxel 4Methods 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Fluorouracil 4Fluorodeoxyglucose F18 4Cyclophosphamide 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3pertuzumab 3fludarabine 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × AZD5305 × Gastrointestinal × Clear all
NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡